CGEM

Cullinan Therapeutics, Inc.

A clinical-stage biopharmaceutical company in Cambridge, Massachusetts that develops experimental therapies for cancer and autoimmune diseases, advancing drug candidates it discovers or licenses through early clinical trials. Founded in 2016 as Cullinan Pharmaceuticals, it rebranded to Cullinan Therapeutics in 2024 to signal its shift beyond oncology into autoimmune conditions. Its name nods to the Cullinan Diamond, the largest gem-quality rough diamond ever found, evoking rarity and brilliance.